Population PK–PD Modeling of Danicopan Add‐On Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria Treated With Ravulizumab or Eculizumab
ABSTRACT Danicopan is a first‐in‐class orally administered complement factor D inhibitor, approved as an add‐on therapy to ravulizumab or eculizumab for the treatment of clinically significant extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). Population pharmacokine...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wiley
2026-03-01
|
| coleção: | CPT: Pharmacometrics & Systems Pharmacology |
| Acesso em linha: | https://doi.org/10.1002/psp4.70209 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|